Systematic Quantitative Modeling of the Natural History of Aicardi Syndrome: A Cross Sectional Study of 245 Published Cases

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2024 Dec 5

PMID 39633384

Authors

Oliver Y Urban

Jan H Driedger

Sven F Garbade

Georg F Hoffmann

Stefan Kolker

Markus Ries

Steffen Syrbe

Affiliations

Soon will be listed here.

Abstract

Purpose: Aicardi syndrome is a rare epileptic encephalopathy, almost exclusively affecting girls. It was first described as a triad of infantile spasms, chorioretinal defects and agenesis of the corpus callosum. The etiology remains unknown and there is uncertainty on best practice therapy and outcome. We aimed at defining quantitative clinical endpoints that will inform future research and clinical trials.

Methods: Quantitative natural history modeling of cases with Aicardi syndrome from published clinical reports. Main outcome measures were age at disease onset, survival and diagnostic delay. Phenotypic features of affected individuals as well as neuroradiological and ophthalmological features were descriptively stated. STROBE criteria were respected.

Results: Two hundred forty-five cases were available for analysis. Median age at disease onset was 2.2 months. Median diagnostic delay was 1 month. Mortality was estimated with 6% at 1 and 17% at 5 years of age. 60% of children showed the classic clinical features, while 40% met the revised diagnostic criteria. We delineate possible predictors of disease severity and of seizure control.

Conclusion: We provide natural history data including geographical localization of 245 published patients with Aicardi syndrome. Quantitative history modeling in rare epileptic encephalopathies will help to raise disease awareness and facilitate future clinical trials as one core element of quantitative systems pharmacology.

References

Garbade S, Zielonka M, Komatsuzaki S, Kolker S, Hoffmann G, Hinderhofer K . Quantitative retrospective natural history modeling for orphan drug development. J Inherit Metab Dis. 2020; 44(1):99-109. DOI: 10.1002/jimd.12304. View

Osborne J, Edwards S, Alber F, Hancock E, Johnson A, Kennedy C . The underlying etiology of infantile spasms (West syndrome): Information from the International Collaborative Infantile Spasms Study (ICISS). Epilepsia. 2019; 60(9):1861-1869. DOI: 10.1111/epi.16305. View

Palmer L, Zetterlund B, Hard A, Steneryd K, Kyllerman M . Aicardi syndrome: follow-up investigation of Swedish children born in 1975-2002. Neuropediatrics. 2007; 38(4):188-92. DOI: 10.1055/s-2007-991146. View

Aicardi J . Aicardi syndrome. Brain Dev. 2005; 27(3):164-71. DOI: 10.1016/j.braindev.2003.11.011. View

Komatsuzaki S, Zielonka M, Mountford W, Kolker S, Hoffmann G, Garbade S . Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases. Genet Med. 2019; 21(10):2208-2215. DOI: 10.1038/s41436-019-0480-7. View

Bai J, Stinchcomb A, Wang J, Earp J, Stern S, Schuck R . Creating a Roadmap to Quantitative Systems Pharmacology-Informed Rare Disease Drug Development: A Workshop Report. Clin Pharmacol Ther. 2023; 115(2):201-205. DOI: 10.1002/cpt.3096. View

Menezes A, MacGregor D, Buncic J . Aicardi syndrome: natural history and possible predictors of severity. Pediatr Neurol. 1994; 11(4):313-8. DOI: 10.1016/0887-8994(94)90008-6. View

Fruhman G, Eble T, Gambhir N, Sutton V, Van den Veyver I, Lewis R . Ophthalmologic findings in Aicardi syndrome. J AAPOS. 2012; 16(3):238-41. PMC: 3650611. DOI: 10.1016/j.jaapos.2012.01.008. View

Bour F, Chiron C, Dulac O, Plouin P . [Electroclinical characteristics of seizures in the Aicardi syndrome]. Rev Electroencephalogr Neurophysiol Clin. 1986; 16(4):341-53. DOI: 10.1016/s0370-4475(86)80024-7. View

10.

Aicardi J, CHEVRIE J, Rousselie F . [Spasma-in-flexion syndrome, callosal agenesis, chorioretinal abnormalities]. Arch Fr Pediatr. 1969; 26(10):1103-20. View

11.

Zielonka M, Garbade S, Kolker S, Hoffmann G, Ries M . A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features. Genet Med. 2017; 20(5):524-530. DOI: 10.1038/gim.2017.133. View

12.

Darke K, Edwards S, Hancock E, Johnson A, Kennedy C, Lux A . Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child. 2010; 95(5):382-6. DOI: 10.1136/adc.2009.160606. View

13.

Glasmacher M, Sutton V, Hopkins B, Eble T, Lewis R, Park Parsons D . Phenotype and management of Aicardi syndrome: new findings from a survey of 69 children. J Child Neurol. 2007; 22(2):176-84. DOI: 10.1177/0883073807300298. View

14.

Hopkins B, Sutton V, Lewis R, Van den Veyver I, Clark G . Neuroimaging aspects of Aicardi syndrome. Am J Med Genet A. 2008; 146A(22):2871-8. PMC: 2597151. DOI: 10.1002/ajmg.a.32537. View

15.

Menezes A, Lewis T, Buncic J . Role of ocular involvement in the prediction of visual development and clinical prognosis in Aicardi syndrome. Br J Ophthalmol. 1996; 80(9):805-11. PMC: 505617. DOI: 10.1136/bjo.80.9.805. View

16.

Prats Vinas J, Martinez Gonzalez M, Garcia Ribes A, Martinez Gonzalez S, Martinez Fernandez R . Callosal agenesis, chorioretinal lacunae, absence of infantile spasms, and normal development: Aicardi syndrome without epilepsy?. Dev Med Child Neurol. 2005; 47(6):419-20. DOI: 10.1017/s0012162205000812. View

17.

Lund C, Bjornvold M, Tuft M, Kostov H, Rosby O, Selmer K . Aicardi syndrome: an epidemiologic and clinical study in Norway. Pediatr Neurol. 2014; 52(2):182-6.e3. DOI: 10.1016/j.pediatrneurol.2014.10.022. View

18.

Masnada S, Pichiecchio A, Formica M, Arrigoni F, Borrelli P, Accorsi P . Basal Ganglia Dysmorphism in Patients With Aicardi Syndrome. Neurology. 2020; 96(9):e1319-e1333. PMC: 8055324. DOI: 10.1212/WNL.0000000000011237. View

19.

Zielonka M, Garbade S, Kolker S, Hoffmann G, Ries M . A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease-an ultra-orphan multisystemic lysosomal storage disorder. Genet Med. 2018; 21(2):347-352. DOI: 10.1038/s41436-018-0051-3. View

20.

Schroter J, Doring J, Garbade S, Hoffmann G, Kolker S, Ries M . Cross-sectional quantitative analysis of the natural history of TUBA1A and TUBB2B tubulinopathies. Genet Med. 2020; 23(3):516-523. PMC: 7935713. DOI: 10.1038/s41436-020-01001-z. View